Pfizer knew drug may prevent Alzheimer's. Why didn't it tell us?

Sydney Morning Herald

5 June 2019 - A team of researchers inside Pfizer made a startling find in 2015: the company's blockbuster rheumatoid arthritis therapy Enbrel, a powerful anti-inflammatory drug, appeared to reduce the risk of Alzheimer's disease by 64 per cent.

The results were from an analysis of hundreds of thousands of insurance claims. Verifying that the drug would actually have that effect in people would require a costly clinical trial - and after several years of internal discussion, Pfizer opted against further investigation and chose not to make the data public, the company confirmed.

Read Sydney Morning Herald article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Medicare , Drug development